Myungmoon Phar Total Liabilities
Myungmoon Phar total liabilities. Based on the latest financial reports, Myungmoon Phar (017180) has total liabilities worth ₩168.00 Billion KRW (≈ $113.85 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 017180 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Myungmoon Phar (2009–2025)
Total liabilities of Myungmoon Phar from 2009 to 2025. This chart illustrates how Myungmoon Phar's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Myungmoon Phar to see how much of total assets are deployed in long-term investments.
Myungmoon Phar Competitors by Total Liabilities
The table below lists competitors of Myungmoon Phar ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oxford Nanopore Technologies Ltd
LSE:ONT
|
UK | GBX141.30 Million |
|
Seoyon Topmetal Co. Ltd
KQ:019770
|
Korea | ₩82.46 Billion |
|
PetMed Express Inc
NASDAQ:PETS
|
USA | $52.25 Million |
|
Mirae Asset Maps Reit 1 Co Ltd
KO:357250
|
Korea | ₩207.61 Billion |
|
Boundless Bio, Inc. Common Stock
NASDAQ:BOLD
|
USA | $58.55 Million |
|
Pamapol S.A.
WAR:PMP
|
Poland | zł500.62 Million |
|
Blaize Holdings, Inc.
NASDAQ:BZAI
|
USA | $59.60 Million |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩9.61 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Myungmoon Phar's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Myungmoon Phar's balance sheet.
Liquidity & Leverage Metrics
Myungmoon Phar Total Liabilities Ratios Explained
Myungmoon Phar total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Myungmoon Phar's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Myungmoon Phar (2009–2025)
The table below shows the annual total liabilities of Myungmoon Phar from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩168.00 Billion ≈ $113.85 Million |
+8.48% |
| 2024-12-31 | ₩154.87 Billion ≈ $104.95 Million |
+4.78% |
| 2023-12-31 | ₩147.79 Billion ≈ $100.16 Million |
+9.33% |
| 2022-12-31 | ₩135.18 Billion ≈ $91.61 Million |
-1.18% |
| 2021-12-31 | ₩136.80 Billion ≈ $92.71 Million |
-10.15% |
| 2020-12-31 | ₩152.25 Billion ≈ $103.18 Million |
-17.37% |
| 2019-12-31 | ₩184.25 Billion ≈ $124.86 Million |
+22.83% |
| 2018-12-31 | ₩150.00 Billion ≈ $101.65 Million |
+12.48% |
| 2017-12-31 | ₩133.36 Billion ≈ $90.37 Million |
+5.51% |
| 2016-12-31 | ₩126.40 Billion ≈ $85.66 Million |
-4.46% |
| 2015-12-31 | ₩132.30 Billion ≈ $89.66 Million |
+12.59% |
| 2014-12-31 | ₩117.51 Billion ≈ $79.63 Million |
-1.43% |
| 2013-12-31 | ₩119.21 Billion ≈ $80.79 Million |
+3.24% |
| 2012-12-31 | ₩115.47 Billion ≈ $78.25 Million |
-3.27% |
| 2011-12-31 | ₩119.37 Billion ≈ $80.90 Million |
+23.03% |
| 2010-12-31 | ₩97.02 Billion ≈ $65.75 Million |
+7.78% |
| 2009-12-31 | ₩90.02 Billion ≈ $61.01 Million |
-- |
About Myungmoon Phar
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hype… Read more